Compare CarMax, Inc (KMX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs ResMed Inc. — how do they compare? CarMax, Inc trades at $52.61 (market cap $7.64B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 4.2× CarMax, Inc's market cap, and ResMed Inc. pays a 1.16% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and ResMed Inc. for 51 Days on average.
| KMX | RMD | |
|---|---|---|
Market Cap | $7.64B | $31.89B |
Volume | 3,610,116 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $275.96 |
52-Week Low | $30.88 | $182.82 |
Typical Hold Time | 49 Days | 51 Days |
Enterprise Value | $25.34B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $53.79, up 0.96% with recent earnings beats driving positive momentum. The stock shows bearish technical signals but strong fundamental improvements with Q2 2026 EPS of $1.16 beating estimates by 58%. Revenue grew 19.5% to $7.9 billion in the latest quarter, while the company's Shift into GEAR strategy shows early success. Valuation metrics remain reasonable with P/E of 25.37 and P/S of 0.28, though net margins remain thin at 1.06%.
KMX presents a turnaround story with improving operational execution but faces margin pressure and high debt levels. The consensus price target of $58.89 suggests 9.5% upside potential, though analyst sentiment remains cautious with 62% hold ratings. Key risks include used car market volatility and interest rate sensitivity, while catalysts include continued execution of the growth strategy and potential share buybacks.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
